[The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats].
The pharmacokinetic properties of dihydroergocristine (DHEC, CAS 17479-19-5) were investigated in rats using a specific radioimmunoassay technique specific for non-metabolized drugs. DHEC, administered intravenously at the dose of 6 mg/kg, showed a plasma profile conforming to an open two-compartment pharmacokinetic model with a long terminal half-life (t1/2 = 13.6 h). DHEC kinetics after oral administration (6 mg/kg) showed two peaks. The first peak (C = 37 micrograms/l) occurred at the first collection point (0.5 h) indicating a quick absorption of the drug. The second peak (C = 34 micrograms/l) occurred at 2 h and may be considered an indication of an enterohepatic cycle. A long terminal half-life (t1/2 = 18.1 h) was observed. An extensive biotransformation of DHEC was indicated by an almost complete absence of unchanged drug in the urine and a high systemic clearance (2.65 l.h-1 x kg-1). A large volume of distribution (52 l.kg-1) was calculated.
Grognet
J M
JM
Laboratoires d'Etudes du Métabolisme des Médicaments, Département de Biologie, Gif-sur-Yvette, Frankreich.
Rivière
R
R
Istin
M
M
Zanotti
A
A
Coppi
G
G
D000284:Administration, Oral; D000818:Animals; D004088:Dihydroergotoxine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D007275:Injections, Intravenous; D008297:Male; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley
D004088:Dihydroergotoxine
Pharmakokinetik von Dihydroergocristin nach intravenöser und oraler Applikation bei Ratten.